ArticleBMC pharmacology & toxicology2026
Nanotechnology-based detoxification of profenofos using red blood cell membrane-coated polymeric nanoparticles.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Mechanism and Application of Traditional Chinese Medicine Nano-Formulations in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrganophosphate (OP) poisoning poses a critical global health challenge due to the absence of specific antidotes. Profenofos (PRF), an organophosphate pesticide, is associated with severe toxicity and high risk of mortality. In this study, a novel biomimetic nanoformulation was synthesized and evaluated for its detoxification effectiveness and safety against profenofos.
methodsThe nanoformulation consisted of red blood cell (RBC) membrane-coated poly(lactic-co-glycolic acid) (PLGA) nanoparticles (RBC-PLGA NPs). RBC membranes were used to cloak PLGA nanoparticles, and the formulation was characterized using a zeta sizer, transmission electron microscopy, and Fourier transform infrared spectroscopy. In vitro assays were performed to evaluate the adsorption of profenofos, while in vivo studies were conducted to assess survival rate, erythrocyte acetylcholinesterase (AChE) activity, and hepatotoxic and renal toxicity markers in a rabbit model.
resultsRBC-PLGA NPs effectively adsorbed profenofos, with removal efficiencies reaching up to 89.92% at a concentration of 4 mg/mL. In vivo experiments showed a significant increase in survival rates following treatment with RBC-PLGA NPs. Moreover, acetylcholinesterase (AChE) activity in erythrocytes was restored by the fourth day post-treatment, and no substantial hepatotoxicity or renal toxicity was observed.
conclusionsThis study demonstrates that RBC membrane-coated PLGA nanoparticles effectively detoxify profenofos, significantly enhancing survival rate and restoring acetylcholinesterase activity without inducing notable toxicity. This work highlights a biomimetic nanoplatform that mimics erythrocyte functionality for toxin detoxification, offering a potential approach for the management of organophosphate poisoning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.